Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed …
Over the last 12 months, insiders at Protara Therapeutics, Inc. have bought $0 and sold $1.75M worth of Protara Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Protara Therapeutics, Inc. have bought $2.31M and sold $1.19M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,065 shares for transaction amount of $34,810 was made by Shefferman Jesse (CEO and President) on 2022‑08‑11.
2024-09-12 | Sale | 10 percent owner | 126,301 0.6048% | $1.71 | $215,836 | +7.51% | ||
2024-09-11 | Sale | 10 percent owner | 32,600 0.1566% | $1.71 | $55,880 | +0.93% | ||
2024-09-10 | Sale | 10 percent owner | 25,500 0.1264% | $1.77 | $45,110 | +7.23% | ||
2024-09-09 | Sale | 10 percent owner | 36,492 0.1821% | $1.89 | $69,141 | +0.54% | ||
2024-07-16 | Sale | 10 percent owner | 11,396 0.0691% | $2.44 | $27,828 | -19.58% | ||
2024-07-11 | Sale | 10 percent owner | 47,993 0.2866% | $2.40 | $115,346 | 0.00% | ||
2024-07-10 | Sale | 10 percent owner | 18,061 0.1036% | $2.31 | $41,685 | 0.00% | ||
2024-07-09 | Sale | 10 percent owner | 8,497 0.0467% | $2.21 | $18,811 | 0.00% | ||
2024-07-01 | Sale | 10 percent owner | 8,288 0.0437% | $2.12 | $17,598 | 0.00% | ||
2024-06-28 | Sale | 10 percent owner | 17,994 0.0927% | $2.07 | $37,334 | 0.00% | ||
2024-06-27 | Sale | 10 percent owner | 46,574 0.2613% | $2.26 | $105,169 | 0.00% | ||
2024-06-25 | Sale | 10 percent owner | 12,725 0.0665% | $2.26 | $28,734 | -7.62% | ||
2024-05-31 | Sale | 10 percent owner | 5,824 0.0292% | $2.90 | $16,895 | -26.88% | ||
2024-05-30 | Sale | 10 percent owner | 9,230 0.0454% | $2.94 | $27,113 | -29.31% | ||
2024-05-22 | Sale | 10 percent owner | 9,800 0.0481% | $3.02 | $29,596 | -31.00% | ||
2024-05-21 | Sale | 10 percent owner | 33,000 0.1671% | $3.06 | $100,838 | -28.84% | ||
2024-05-17 | Sale | 10 percent owner | 70,885 0.3032% | $3.25 | $230,326 | -32.04% | ||
2024-05-10 | Sale | 10 percent owner | 151,700 0.7648% | $3.11 | $472,424 | -28.52% | ||
2024-05-09 | Sale | 10 percent owner | 30,600 0.1541% | $3.09 | $94,526 | -27.55% | ||
2022-12-30 | Sale | director | 15,473 0.1389% | $2.71 | $41,949 | -0.75% |
Opaleye Management Inc. | 10 percent owner | 45000 0.2181% | $2.47 | 15 | 20 | <0.0001% |
O'Leary Brendan | director | 1387198 6.7242% | $2.47 | 1 | 0 | |
Abingworth LLP | 10 percent owner | 950000 4.605% | $2.47 | 1 | 0 | |
Haines Timothy | 950000 4.605% | $2.47 | 1 | 0 | ||
Shefferman Jesse | CEO and President | 879441 4.263% | $2.47 | 1 | 0 | <0.0001% |
Opaleye Management Inc | $10.8M | 13.08 | 2.69M | 0% | +$0 | 2.38 | |
The Vanguard Group | $1.71M | 2.08 | 427,612 | 0% | +$0 | <0.0001 | |
Boxer Capital, LLC | $839,000.00 | 1.02 | 209,227 | 0% | +$0 | 0.02 | |
Ikarian Capital LLC | $812,830.00 | 0.98 | 202,701 | +7.44% | +$56,288.30 | 0.11 | |
Baker Bros Advisors LP | $800,681.00 | 0.97 | 199,671 | 0% | +$0 | 0.01 |